Sequentially releasing dual-drug-loaded PLGA–casein core/shell nanomedicine: Design, synthesis, biocompatibility and pharmacokinetics

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

“…[5][6][7] Researchers have been interested in exploring anticancer formulations in the form of nanomedicines, either as a combination of multiple drugs loaded into nanocarriers (combinatorial nanomedicines) or as drug-loaded nanocarriers that are actively targeted to specific overexpressed surface receptors such as EGFR (targeted nanomedicines) to improve the anticancer potential. 8,9 Alternative cancer nanomedicines following molecularly targeted strategies have been developed to enhance the therapeutic efficiency of conventional chemotherapeutics. Our research group has previously reported the development of CET (MAb)-conjugated docetaxel (DOCT)-loaded poly(γ-glutamic acid) (γ-PGA) nanoparticles (Nps) and tested their in vitro targeting and therapeutic efficacy in EGFR +ve colorectal (HT-29) and A549 (non-small cell lung carcinoma) cell lines.…”

“…The enhanced t 1/2 and K el values support the fact that the Nps resulted in longer circulation in vivo. 9,56 The organ distribution data showed early liver accumulation for free DOCT and it was reduced over time, which suggested hepatic metabolism of DOCT. The nanoformulated DOCT was observed to accumulate in all of the tested organs, but at a reduced level compared with that of free DOCT.…”

Core–shell designed scaffolds for drug delivery and tissue engineering

“…Drug release is largely diffusion-controlled, where the drug molecules diffuse out through the shell barriers. The core can also be filled with water-soluble polymers, such as chitosan, alginate or poly(N-isopropylacrylamide) (PNIPAAm), which can also hold the drug molecules [42][43][44]. Compared to hollow nanospheres, this type of material-filled core-shell nanospheres can sustain the drug molecules for prolonged periods (Fig.…”

Tri-Needle Coaxial Electrospray Engineering of Magnetic Polymer Yolk–Shell Particles Possessing Dual-Imaging Modality, Multiagent Compartments, and Trigger Release Potential

“…Over the last two decades, explorations into synergistic chemotherapies (utilizing two or more actives) to treat various types of cancers have broadened, and numerous efforts have focused on the role and development of advanced carriers systems. [17][18][33][34] For drug carrier design; hydrophilicity of incorporated active is a crucial factor, not only for matrix dispersibility but to achieve ideal therapeutic release. 16,35 Therefore, development of advanced carrier systems capable of delivering active(s) with varying hydrophilicities is extremely valuable.…”

“…[17][18] One such area of focus has centered on encapsulated polymeric particulate systems; with conceptual designs demonstrated in bi-layer, multi-layered and several other complex systems. [19][20][21] Among all polymeric particulate formats with compartmentalized (interior) structures, yolkshell particles (YSPs) appear least explored although they display unique features and physical properties; including low densities, large surface areas and excellent loading capacities.…”